Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05492214
Other study ID # NSFC.82173528
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 22, 2022
Est. completion date December 2024

Study information

Verified date May 2023
Source Peking University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled trial, aiming to evaluate the effects of time window for umbilical cord clamping during cesarean section on the health outcomes of offspring hemoglobin,maternal blood loss,and children's growth and development. It will be conducted in Liuyang city and Huantai county of China, and the targeted sample size is 360 (180 in each site). All the eligible pregnant women will be randomly assigned to one of the four groups (three intervention groups and one control group), and their babies will be followed up to 18 months of age.


Description:

The World Health Organization and American College of Obstetricians and Gynecologists have recommended a delay in umbilical cord clamping after birth, irrespective of delivery modes, which was based on studies from vaginal deliveries rather than cesareans. In cesareans, the optimal time window for umbilical cord clamping has not been determined, and the relevant safety data are limited. In this randomized study, the investigators aim to evaluate the impacts of time window for umbilical cord clamping during cesarean section on maternal and child health outcomes, and to evaluate the optimal timing of the clamping. The investigators are planning to enroll 360 pregnant women scheduled for cesareans, and to randomly allocate them into four groups: the umbilical cord will be clamped within 15 seconds (immediately), or delayed after deliveries for 30, 60, and 90 seconds, respectively. Babies will be followed up at 3, 6, 12, and 18 months of age. Maternal hemoglobin before and after cesareans, neonatal hemoglobin, children's hemoglobin at 6, 12, 18 months of age will be measured. At each follow-up visit, children's length and weight will be measured, their development will be assessed, and a questionnaire survey including information on feeding, sleep, and medication will be conducted. The primary outcomes are the neonatal hemoglobin and the change in maternal hemoglobin. The secondary outcomes include the incidence rate of neonatal anemia and jaundice, Apgar score, the incidence rate of neonatal intensive care unit (NICU) admission, placental weight, maternal hemoglobin after the cesarean, estimated maternal blood loss, and the incidence rate of maternal blood transfusion. In addition, the children's hemoglobin, anemia, growth and development are considered as the exploratory secondary outcomes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 360
Est. completion date December 2024
Est. primary completion date May 8, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - local resident in Liuyang city, Huantai county and their surrounding areas - Singleton pregnancy - Elective caesarean, or cesarean section after the start of labor but the cervix is less than 3 cm - Term pregnancy (=37 weeks of gestation), and the fetal weight was estimated =2500g by intrauterine ultrasound - Written informed consent is obtained Exclusion Criteria: - Pregnant women with the following risk factors: severe hypertension (systolic blood pressure =160 mmHg and/or diastolic blood pressure =110mmHg), preeclampsia, chronic hypertension with preeclampsia, diabetes mellitus with severe microangiopathy, placenta previa, placenta implantation, placental abruption, intrauterine distress, prenatal infection, severe anemia (hemoglobin<7g/dL), coagulation disorders, thrombosis disease - Plan to retain cord blood - Rh-negative pregnant women - Prenatal diagnosis of fetal abnormalities which may lead to difficulties in cesareans or adverse pregnancy outcomes, such as abnormal heart monitoring, fetal distress, malformation, anemia, and intrauterine growth restrictions - Other conditions not suitable for intervention as judged by obstetricians

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Delayed cord clamping (30s)
The same as that stated in arm descriptions.
Delayed cord clamping (60s)
The same as that stated in arm descriptions.
Delayed cord clamping (90s)
The same as that stated in arm descriptions.

Locations

Country Name City State
China Liuyang Maternal and Child Health Care Hospital Liuyang Hunan
China Women and Children's Health Care Hospital of Huantai Zibo Shandong

Sponsors (4)

Lead Sponsor Collaborator
Peking University Liuyang Maternal and Child Health Care Hospital, National Natural Science Foundation of China, Women and Children's Health Care Hospital of Huantai

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The children's hemoglobin In fingertip blood At 6, 12, 18 months of age
Other The children's anemia Defined as hemoglobin <110 g/L At 6, 12, 18 months of age
Other The children's length In Z-score At 3, 6, 12, 18 months of age
Other The children's weight In Z-score At 3, 6, 12, 18 months of age
Other The results of Denver Developmental Screening Test The abnormal rate At 3, 6, 12, 18 months of age
Primary The neonatal hemoglobin In the heel blood Within 72 hours after birth
Primary The change in maternal hemoglobin Difference in maternal hemoglobin levels before and after the cesarean Within 72 hours before the cesarean, and within 72 hours after the cesarean
Secondary The incidence rate of neonatal anemia Defined as hemoglobin <145g/L Within 72 hours after birth
Secondary The incidence rate of neonatal jaundice The incidence rate of neonatal jaundice Before discharging from hospitals, usually within 1 week after birth
Secondary Apgar score An indicator for the activity, pulse, grimace, appearance, and respiration of neonates. It ranges from 0 to 10, the higher the better. At 1 min, 5 min, and 10 min after birth
Secondary The incidence rate of neonatal intensive care unit admission The incidence rate of neonatal intensive care unit admission Before discharging from hospitals, usually within 1 week after birth
Secondary Placental weight In grams At birth
Secondary Maternal hemoglobin after the cesarean In venous blood Within 72 hours after the cesarean
Secondary Estimated maternal blood loss By volume-method and area-method During the cesarean
Secondary The incidence rate of maternal blood transfusion The incidence rate of maternal blood transfusion At delivery
See also
  Status Clinical Trial Phase
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Completed NCT05426564 - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Withdrawn NCT05518279 - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures Phase 3
Enrolling by invitation NCT02910115 - Cooling the Uterus in C-section After Dysfunctional Labor N/A
Completed NCT02569658 - Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty N/A
Completed NCT01048658 - Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures Phase 4
Terminated NCT02908516 - Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures Phase 4
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Recruiting NCT06403163 - Transfusion Surveillance in Anaesthesia
Recruiting NCT02265562 - Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy Phase 3
Completed NCT02083809 - Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation N/A
Completed NCT02312440 - Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty Phase 3
Completed NCT01895101 - The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients Phase 4
Completed NCT00990288 - The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery Phase 4
Completed NCT01099475 - Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery N/A
Completed NCT03365999 - Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. Phase 2
Recruiting NCT05550623 - Pneumatic Tourniquet Versus no Tourniquet in Transfemoral Amputation N/A
Completed NCT05012202 - Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women
Completed NCT02311309 - Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery N/A
Withdrawn NCT01712971 - Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery N/A